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Abstract
The aims of this study were: to characterise and compare plasma concentrations of midkine (MDK) in normal healthy 
women with concentrations observed in women with ovarian cancer; and to establish and compare the performance 
of MDK with that of anterior gradient 2 protein (AGR2) and CA125 in the development of multi-analyte classification 
algorithms for ovarian cancer. Median plasma concentrations of immunoreactive MDK, AGR2 and CA125 were 
significantly greater in the case cohort (909 pg/ml, 765 pg/ml and 502 U/ml, respectively n = 46) than in the control 
cohort (383 pg/ml, 188 pg/ml and 13 U/ml, respectively n = 61) (p < 0.001). The area under the receiver operator 
characteristic curve (AUC) for MDK and AGR2 was not significantly different (0.734 ± 0.046 and 0.784 ± 0.049, 
respectively, mean ± SE) but were both significantly less than the AUC for CA125 (0.934 ± 0.030, p < 0.003). When 
subjected to stochastic gradient boosted logistic regression modelling, the AUC of the multi-analyte panel (MDK, AGR2 
and CA125, 0.988 ± 0.010) was significantly greater than that of CA125 alone (0.934 ± 0.030, p = 0.035). The sensitivity 
and specificity of the multi-analyte algorithm were 95.2 and 97.7%, respectively. Within the study cohort, CA125 
displayed a sensitivity and specificity of 87.0 and 94.6%, respectively. The data obtained in this study confirm that both 
MDK and AGR2 individually display utility as biomarkers for ovarian cancer and that in a multi-analyte panel 
significantly improve the diagnostic utility of CA125 in symptomatic women.
Introduction
Each year, more than 200,000 women are diagnosed with
ovarian cancer. Ovarian cancer is the 8th most common
cancer in women and the 2nd most common type of gyne-
cological cancer in the world. In the USA, the prevalence
of ovarian cancer in postmenopausal women is 1 in 2,500
and the lifetime risk of a woman developing ovarian can-
cer is 1 in 72. The age-adjusted incidence and death rates
for ovarian cancer are 13.3 and 8.8 per 100,000, respec-
tively. The average five-year survival rate for ovarian can-
cer patients is ~46%. This high overall mortality is a
consequence of a failure to detect this disease at an early
stage. As there are no clinically overt early symptoms,
most women (~75%) are first diagnosed with dissemi-
nated disease (Stage III/IV) when prognosis is poor.
Despite recent progress in chemotherapeutic treatments,
the diagnosis of late stage disease is associated with a
five-year survival rate of ~30%. In contrast, when ovarian
cancer is identified at an early stage, five year survival
increases to ~90%. Thus, the development of more accu-
rate and earlier detection tests for this disease are
undoubtedly the number one priority for achieving long-
term reduction of mortality from ovarian cancer [1].
Currently, plasma or serum CA125 concentration is the
best characterised and most widely used ovarian cancer
biomarker and is elevated in more than 80% of patients
with epithelial ovarian cancer [2]. CA125 concentrations,
how eve r ,  ar e  incr eased in onl y ~  50% of  pa t ie n ts wit h
Stage I disease [3]. Thus, more accurate and earlier detec-
tion tests are requisite to reducing the mortality associ-
ated with this disease.
Previously, we and others have reported the utility of
combining biomarkers to develop classification algo-
rithms for identifying women with ovarian cancer [4-10].
Such studies establish proof-of-concept and the potential
to improve diagnostic efficiency by combining multiple
ovarian cancer biomarkers. The sensitivity and specificity
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of such panels, however, must be further improved and
additional informative biomarkers that contribute to
multivariate modelling need to be identified.
The purpose of this study was to characterise changes
in the plasma concentrations of MDK in association with
ovarian cancer and compare its diagnostic performance
(as assessed by the AUC) with that of AGR2 (a recently
reported circulating biomarker of ovarian cancer [11])
and CA125 in symptomatic women. Available data are
consistent with a putative role for both AGR2 and MDK
in oncogenesis and tumor progression, including ovarian
cancer.
Materials and methods
Control and ovarian cancer plasma samples
Plasma samples were collected from healthy women
(median age 52, range 32-69 years, n = 61) and women at
the time of diagnosis of ovarian cancer and before treat-
ment (median age 61, range 24-69 years, n = 46). The
project was approved by the Mercy Hospital for Women
Human Research and Ethics Committee (R09/06). All
case samples and part of the control sample set used in
this study were provided by the Biobank at Peter MacCal-
lum Cancer Research Institute (Melbourne, Australia)
and all subjects participated in the study after signing an
informed written consent. Blood (10 ml) was collected
via vena puncture into EDTA vacutainer tubes and sam-
ples were centrifuged at 1000 g for 10 min within 20-30
min of collection. Plasma was stored as 250-1000 μl ali-
quots at -80°C until assayed. Ovarian tumor classification
was based on the FIGO staging system, however, no stage
IV tumors were identified for inclusion in this study.
Study Design
The study was a retrospective, case-control design (i.e. a
phase 2 biomarker trial [12] involving 107 plasma sam-
ples (see Table 1) obtained from 61 controls and 46 cases
(i.e. women previously diagnosed with ovarian cancer).
Inclusion and exclusion criteria are presented in Table 2.
The primary outcomes of the study were: quantification
of plasma concentrations of ir MDK and evaluation of its
diagnostic performance (as defined by AUC); and com-
parison with AGR2 and CA125 concentrations measured
in the same cohort. In addition, the contribution for these
biomarkers to multi-analyte classification models was
determined.
Biomarker Quantitation
Plasma concentrations of MDK were quantified by sand-
wich ELISA assay (Peprotech, Rocky Hill, NJ, USA) that
utilises rabbit antibodies raised to human midkine for
both capture and detection stages of the assay. The assay
was performed in Costar half-well immunoassay plates
(Corning) coated with 50 μl of capture antibody at a con-
centration of 1 ug/ml in 50 mM carbonate buffer and
incubated at 4°C for 18 h. Following four washes in PBS/
Tween20 (Sigma), the plate was blocked with 150 μl/well
of 0.1% BSA (Sigma) in PBS, for one hour at room tem-
perature. Plasma samples diluted 1:2 in PBS containing
0.05% Tween20 and 0.1% BSA were applied to the plate
following blocking, alongside a standard curve, from
2000 pg/ml down in doubling dilutions, constructed from
a stock recombinant midkine. Samples and standards
were incubated (50 μl/well) at room temperature for 2 h
following which the plate was washed a further three
times with wash buffer. Detection of bound midkine was
made using 50 μl/well of biotinylated detection antibody
at a concentration of 1.0 ug/ml for 2 h at room tempera-
ture. Following a further four washes the plate was incu-
bated with a 1:2000 dilution of avidin-HRP conjugate for
30 min. Finally the plate was washed four times and 100
μl of OPD substrate added to the wells and incubated for
30 min in the dark. Prior to reading on a Multiskan
Ascent the reaction is topped by addition of 25 μl of 3 M
sulphuric acid.
AGR2 concentrations were quantified using an in-
house sandwich ELISA employing a mouse monoclonal
antibody (7A10) to a peptide epitope (KPGAKKDTKD-
SRPKL) of AGR2 that displays no measurable cross reac-
tivity with AGR3, as previously reported [11].
CA-125 was quantified using Roche CA-125 Elecsys II
assay (Roche, Mannheim, Germany, LD = 0.6 U/ml; intra-
and inter-assay coefficients of variation CV = 3.3% and
4.3%) as previously reported [8].
Statistical Analyses
Two sample group comparisons of median values were
assessed by Mann Whitney tests (STAT 9.2, Stata Corpo-
ration, College Station, TX, USA). Correlation between
two sample groups was assessed by Spearman's rank cor-
relations using the Bonferoni correction). Multiple group
comparisons were assessed by Kruskal-Wallis tests [13].
Dunn's tests [14] were used for post-hoc two sample
comparisons. A p value of < 0.05 was ascribed as statisti-
cally significant.
Multivariate Modelling
Binomial classification algorithms were generated, based
upon biomarker data obtained in this study, using a
boosted logistic regression algorithm with Weka Data
Mining Software (Ver 3-6-1, [15,16]). The predicted pos-
terior probability values reported (i.e. the likelihood that
a sample came from a woman with ovarian cancer, that is
ρP) were used to generate receiver operator characteristic
curves. Sensitivity and specificity were calculated based
on the numbers of correctly and incorrectly classified
samples. For classification of samples based on conven-Rice et al. Journal of Experimental & Clinical Cancer Research 2010, 29:62
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tional plasma CA-125 concentrations, a threshold value
of ≥ 35 U/ml was used as indicative of ovarian cancer.
ROC Curve Comparisons
For individual biomarkers, plasma concentration data
were used to generate ROC curves (MedCalc, MedCalc
Software bvba, Mariakerke Belgium). AUCs were calcu-
lated using the Wilcoxon statistic [17]. The diagnostic
performance of the biomarkers was assessed by compari-
son of the area under ROC curves using the method of
Hanley and McNeil [18] for ROCs derived from the same
cases. A threshold value of 0.500 was used for classifica-
tion of samples based on ρP. Values of > 0.500 being clas-
sified as ovarian disease and samples with a calculated
value < 0.500 being classified as normal.
Results
Cohort Characteristics
The median age (range) of the control and case cohort
were 52 years (32 - 69, n = 61) and 61 years (24 - 81, n =
46), respectively. The distribution of type and stage of
ovarian cancer within the case cohort is presented in
Table 1. Of the cases included in this study, 76% (i.e. 35
cases) were early stage disease (i.e. Stages I and II). The
median CA125 plasma concentrations were 13 U/ml
(range 3 - 84) for controls and 502 U/ml (5 - 10,209) for
Table 1: Distribution of Ovarian Tumor Types and Stages of ovarian cancer patients used for plasma AGR2 and CA125 
measurements.
All Tumors Stage I Stage II Stage III Unstaged
Serous 2 931 79
Mucinous 5131
Endometrioid 422
Clear Cell 211
Mixed Mullerian 312
Untyped 321
Total 4 692 6 1 01
Table 2: Inclusion and exclusion criteria for inclusion of patient samples in the study.
Inclusion Criteria Exclusion Criteria
Age 18-80 Chemotherapy, biologic therapy or any other investigational drug 
for any reason within 28 days prior to sampling.
Newly diagnosed, histologically or pathologically confirmed 
diagnosis of epithelial carcinoma of the ovary.
Except for cancer-related abnormalities, patients should not have 
unstable or pre-existing major medical conditions.
No NSAID or prednisone use within 14 days of sampling. Major surgical procedure, open biopsy, or significant traumatic 
injury within 28 days prior to sampling
No previous chemotherapy or radiation therapy. Minor surgical procedures, fine needle aspirations or core biopsies 
within 7 days prior to sampling
No concurrent disease(s) Serious, non-healing wound, ulcer, or bone
Signed informed client consentRice et al. Journal of Experimental & Clinical Cancer Research 2010, 29:62
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cases. In 3 controls, CA125 concentration was ≥ 35 U/ml.
In 6 cases, CA125 concentration was < 35 U/ml. At a
threshold of 35 U/ml, the sensitivity and specificity of
CA125 were 87.0 and 95.1%, respectively.
Variation with Disease State, Stage and Tumor Type
The variation in plasma analyte concentrations for con-
trol and case cohorts is presented in Figure 1. Median
plasma concentrations of immunoreactive MDK, AGR2
and CA125 were significantly greater in the case cohort
(909 pg/ml, 765 pg/ml and 502 U/ml, respectively n = 46)
than in the control (383 pg/ml, 188 pg/ml and 13 U/ml,
respectively n = 61) cohort (p < 0.001, as assessed by
Mann Whitney tests). Within control or case cohorts,
plasma concentrations of AGR2 displayed no significant
correlations with either CA125 or midkine concentra-
tions (as assessed by Spearman's correlation, p > 0.05).
Within the case cohort, MDK plasma concentrations sig-
nificantly correlated with CA125 concentrations (ρ =
0.383, p < 0.01). Data were further analysed with respect
to tumor type and Stage (Table 3). No statistically signifi-
cant effects of either tumor type or stage on biomarker
plasma concentrations were identified (Kruskal-Wallis
one-way analysis of variance, p > 0.05).
Receiver Operator Characteristic Curve Analysis and Multi-
analyte Modelling
ROC curves were generated for each individual analyte.
The area under the curve (AUC) for MDK, AGR2 and
CA125 was: 0.753 ± 0.049; 0.768 ± 0.048; 0.934 ± 0.027,
respectively (AUC ± SEM). There was no significant dif-
ference between the AUC for midkine and AGR2. The
AUC for CA125 was significantly greater than that for
both midkine and AGR2 (p < 0.001, Table 4).
A binomial classification algorithm was developed by
subjecting the observed plasma concentrations for MDK,
AGR2 and CA125 to stochastic gradient boosted logistic
regression analysis [19]. A ρP value was calculated for
each patient set of biomarkers and used to generate a
ROC curve (Figure 2). The AUC for the multi-analyte
panel (0.988 ± 0.011) was significantly greater than that
for MDK (p < 0.001), AGR2 (p = 0.001) and CA125 (p =
0.038) (Figure 3). The sensitivity and specificity of the
multi-analyte algorithm were 95.2 and 97.7%, respec-
tively. Within the study cohort, CA125 displayed a sensi-
tivity and specificity of 87.0 and 94.6%, respectively.
Discussion
The aims of this study were: to characterise and compare
plasma concentrations of midkine (MDK) in normal
healthy women with concentrations observed in women
with ovarian cancer; and to establish and compare the
performance of MDK with that of anterior gradient 2
protein (AGR2) and CA125 in the development of multi-
Figure 1 Plasma biomarker concentrations. The median plasma 
concentration within each group (normal women (controls) n = 61 
and women with ovarian cancer (cases) n = 46) is represented by the 
horizontal line. Biomarker concentrations were significantly greater in 
case cohorts (solid symbols) when compared to their respective con-
trol cohort (open symbols) (p < 0.001, Mann Whitney tests). Data are 
presented as log (plasma concentration). CA125 as U/ml; and MDK and 
AGR2 as pg/ml.
Table 3: Case cohort variation in plasma analyte concentration by 
stage of disease and tumor type, as assessed by Kruskal-Wallis 
One Way Analysis of Variance (Stage and Tumor Type).
Analyte Stage n = 45# (p) Tumor Type n = 43† (p)
MDK 0.722 0.839
AGR2 0.776 0.334
CA125 0.524 0.214
# 1 sample was unstaged
† 3 samples were not typed
Table 4: Comparison of AUC for MDK, AGR2, CA125 and multi-
analyte panel Data represent AUC ± standard errors (SEM).
Analyte AUC ± SEM p
CA125 0.934 ± 0.027
MDK 0.753 ± 0.049 < 0.001
AGR2 0.768 ± 0.048 = 0.001
Multi-analyte Algorithm 0.988 ± 0.011 = 0.038
The difference in the AUC of MDK, AGR2 and the multi-analyte 
algorithm are compared to that of CA125. The AUC of MDK was not 
statistically significantly different from the AUC of AGR2 (p > 0.05).Rice et al. Journal of Experimental & Clinical Cancer Research 2010, 29:62
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analyte classification algorithms for ovarian cancer. A ret-
rospective, case-control study was conducted to compare
the diagnostic performance (as measured by AUC) of
plasma ir MDK and ir AGR2 individually or in combina-
tion with CA125 with the performance of CA125 alone.
Biomarker plasma concentrations were quantified in nor-
mal healthy women and women with confirmed ovarian
cancer. The data obtained confirm the utility of both
MDK and AGR2 as plasma biomarkers for ovarian cancer
and, when combined in a multi-analyte panel, signifi-
cantly improve the diagnostic efficiency of CA125.
The median plasma concentrations of both ir MDK and
ir AGR2 were significantly greater in women with ovarian
cancer (909 pg/ml and 765 pg/ml, respectively n = 46)
than in normal healthy women (383 pg/ml and188 pg/ml,
respectively n = 61) (p < 0.001). There is a paucity of data
characterising the plasma concentrations of MDK in
ovarian cancer patients. Salama et al. (2006) [20]
reported a similar change in serum MDK concentrations
in 15 women with ovarian carcinoma (i.e. > 500 pg/ml)
and 49 controls (i.e. < 500 pg/ml) to those concentrations
reported in this study. Within the present study cohort,
plasma concentrations of MDK and AGR2 were not sig-
nificantly altered by tumor type or stage of disease. It is of
note, however, that plasma concentrations of MDK and
AGR2 display differential responsiveness in women with
ovarian cancer when compared to CA125. In the case
cohort, plasma concentrations of MDK but not AGR2
correlated significantly with CA125 concentrations. The
lack of correlation between AGR2 and CA125 and AGR2
and midkine plasma concentrations in women with ovar-
ian cancer may provide an opportunity to improve diag-
nostic efficiency by reducing the false negative rate and
may be reflective of stage and/or tumor type- differential
expression of AGR2 and CA125. This study, however, was
not designed to definitively assess the relationship
between analyte plasma concentration and disease stage
and type and a larger cohort study would be required to
resolve these relationships.
The diagnostic utility of MDK and AGR2 was further
demonstrated by ROC curve analysis. It is acknowledged
that good risk prediction models have an AUC > 0.7 [21].
The AUCs for MDK and AGR2 were 0.753 and 0.768,
respectively. Individually, neither MDK nor AGR2 was
superior to the classification efficiency of CA125 alone.
In combination with CA125, however, MDK and AGR2
significantly increased AUC by more than 0.05 to greater
than 0.98. Within the study cohort, the increased diag-
nostic efficiency of the multi-analyte algorithm reduced
false positive and false negative rates by more than 50%
when compared with CA125 alone. The sensitivity and
specificity of the multi-analyte algorithm was 95.2 and
97.7%, respectively. It is of note that the performance of
the three analyte algorithm developed in it this study, at
least, is comparable to that of previously reported algo-
rithms containing a greater number of biomarkers (e.g.
[8]).
The involvement of both MDK and AGR2 in oncogene-
sis and tumor progression has been previously reported.
MDK is a 13-kDa secreted heparin-binding growth factor
[22,23], first identified in 1988 [24] and recent implicated
in cell proliferation and survival, migration and angiogen-
esis [25-31]. Furthermore, MDK expression is induced in
association with oncogenesis, inflammation and wound
healing [32,33] and is over-expressed in various human
cancers, including ovarian cancer [34-38] and may con-
tribute to the development of chemotherapy drug resis-
tance [39].
Figure 2 Predicted posterior probability values (ρP). Values were 
generated by multivariate modelling for each patient set of biomarkers 
for Case and Control cohorts.
Figure 3 ROC curve comparison. ROC curves are displayed for the 
multi-analyte algorithm (midkine, AGR2 and CA125) and CA125 alone. 
The AUC (± SEM) for the multi-analyte panel (black diamond) (0.988 ± 
0.010) was significantly greater than that of CA125 alone (black circle) 
(0.934 ± 0.030, p = 0.035).Rice et al. Journal of Experimental & Clinical Cancer Research 2010, 29:62
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Anterior Gradient 2 protein is the protein product of a
proto-oncogene (7p21.3) implicated in cell migration, dif-
ferentiation and proliferation and is over-expressed in
cancer of various origins. In human breast cancer cells,
A G R 2  e x p r e s s i o n  c o r r e l a t e s  p o s i t i v e l y  w i t h  e s t r o g e n
receptor [40] and negatively with epidermal growth fac-
tor receptor expression [41]. These data are consistent
with the hypothesis that AGR2 may play a role in the dif-
ferentiation of hormonally responsive breast cancers
[40,42]. More recently, a role for AGR2 in the aetiology of
ovarian epithelial cancer has been proposed. AGR2 gene
expression is significantly increased in ovarian carcino-
mas, particularly in mucinous tumors [43]. In non-neo-
plastic ovarian epithelial tissue, immunoreactive (ir)
AGR2 was not detectable, however, virtually all ovarian
tumors of variable histotypes stain positively for irAGR2.
In addition, AGR2 has been reported to be released into
the circulation of ovarian cancer patients [11]. Previous
studies have reported that overexpression of AGR2 may
promote the development of metastatic phenotype in
b e n i g n  b r e a s t  c a n c e r  c e l l  [ 4 2 ]  a n d  s e c r e t e d  A G R 2  h a s
been implicated in promoting proliferation of pancreatic
cell lines in culture [44]. In addition, circulating tumor
cells from patients with advanced metastatic disease dis-
play elevated AGR2 gene expression [45] suggesting that
AGR2 may play a functional role in metastasis or may
represent a useful biomarker of circulating tumor cells
[46].
Conclusion
The data obtained in this study confirm that the measure-
ment of plasma concentrations of MDK and AGR2 indi-
vidually display utility as biomarkers for ovarian cancer
and that when included in a multi-analyte panel may sig-
nificantly improve the diagnostic utility of CA125 in
symptomatic women.
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